ApoE elevation is associated with the persistence of psychotic experiences from age 12 to age 18: Evidence from the ALSPAC birth cohort by Sabherwal, Sophie et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/123027/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Sabherwal, Sophie, Föcking, Melanie, English, Jane A., Fitzsimons, Stephen, Hryniewiecka,
Magdalena, Wynne, Kieran, Scaife, Caitriona, Healy, Colm, Cannon, Mary, Belton, Orina, Zammit,
Stanley, Cagney, Gerard and Cotter, David R. 2019. ApoE elevation is associated with the
persistence of psychotic experiences from age 12 to age 18: Evidence from the ALSPAC birth
cohort. Schizophrenia Research 209 , pp. 141-147. 10.1016/j.schres.2019.05.002 file 
Publishers page: http://dx.doi.org/10.1016/j.schres.2019.05.002
<http://dx.doi.org/10.1016/j.schres.2019.05.002>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
ApoE elevation is associated with the Persistence of Psychotic Experiences from age 11 to 
age 18: Evidence from the ALSPAC Birth Cohort  
Sophie Sabherwal
1
, Melanie Föcking
1
, Jane A English
1
, Stephen Fitzsimons
2
, Magdalena 
Hryniewiecka
1
, Kieran Wynne
2
, Caitriona Scaife
2
, Colm Healy
1
, Mary Cannon
1
, Orina Belton
2
, 
Stanley Zammit
3,4
, Gerard Cagney
2
, David R. Cotter
*1
 
1
Department of Psychiatry, Royal College of Surgeons in Ireland (RCSI), Beaumont Hospital, 
Dublin, Ireland; 
2
School of Biomolecular and Biomedical Science, Conway Institute, 
University College Dublin, Dublin, Ireland.
 3
MRC Centre for Neuropsychiatric Genetics and 
Genomics, Cardiff University, Cardiff, UK; 
4
Centre for Academic Mental Health, Bristol 
Medical School, University of Bristol, Bristol, UK 
To whom correspondence should be addressed; Royal College of Surgeons in Ireland 
Education & Research Centre, Beaumont Hospital, Beaumont, Dublin 9, Ireland; tel: 01-809-
3862, fax: 01-809-3741, e-mail: drcotter@rcsi.ie 
Word count of the abstract: 149 
Word count of the manuscript: 3780 
Number of figures: 2 
Number of tables: 2 
Supplemental information: Supplemental methods, 1 table, 1 figure 
Abstract 
Apolipoproteins, which play important roles in lipid metabolism, innate immunity and 
synaptic signalling, have been implicated in first episode psychosis and schizophrenia. This is 
the first study to investigate plasma apolipoprotein expression in children with psychotic 
experiences that persist into adulthood. Here, using semi-targeted proteomic analysis we 
compared plasma apolipoprotein expression levels in age 11 subjects who reported 
psychotic experiences at both age 11 and age 18 (n=38) with age-matched controls who 
only experienced psychotic experiences (PEs) at age 11 (n=38). Participants were recruited 
from the UK Avon Longitudinal Study of Parents and Children (ALSPAC) cohort who 
participated in psychiatric assessment interviews at ages 12 and 18.  We identified apoE, a 
ŵarker of Alzheiŵer͛s Disease, to be significantly up regulated (p<0.003) in those with 
persistent psychotic experiences.  We confirmed this finding in these samples using ELISA. 
Our findings indicate elevated plasma apoE in age 11 children who experience PEs is 
associated with persistence psychotic experiences.  
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1. Introduction
The early detection and treatment of psychosis patients significantly improves their clinical 
outcome. Consequently, any clinical or biological marker of future psychotic experiences are 
potentially of great clinical value. However, the clinical characteristics of those at risk of 
future psychotic disorder, such as those in the at-risk-mental state, ultra-high risk (UHR) and 
clinical-high risk (CHR) have been found to be of relatively limited predictive value (Welsh & 
Tiffin ., 2013). Risk calculators have been developed which include neuropsychological, 
neuroimaging and biological measures (Cannon et al., 2016, Clark et al., 2016). 
In relation to biological markers, the field of blood biomarker discovery for disorders of the 
brain has been legitimized by replicable blood-based biomarker findings in Alzheiŵer͚s 
disease (Ovod et al., 2017, Nabers et al., 2018, Kaneko et al., 2014). This is of huge 
significance to psychiatry and neurology due to the relative ease of accessibility to patient 
blood in comparison to other biological samples. In addition, blood confers a significant 
advantage over other peripheral samples in that it can be taken at any stage during the 
course of illness, unlike cerebrospinal fluid (CSF) for instance. These factors are driving the 
search for predictive (risk-calculating) blood biomarkers for central nervous system 
disorders such as schizophrenia and psychosis (Perkins et al., 2015, Chan et al., 2015).  
Altered levels of plasma apolipoproteins have been observed in schizophrenia and first 
episode psychosis (FEP)  and indeed are some of the most replicable findings in blood 
biomarkers studies of FEP (Sabherwal et al. 2016). Specifically, reduced plasma 
apolipoprotein A1 (apoA1), a prognostic marker for cardiovascular disease, was found to be 
reduced in the blood of drug free schizophrenia and FEP patients by six independent 
proteomic studies (Sabherwal et al. 2016). Seven other apolipoproteins have also been 
found to be altered in drug free schizophrenia and FEP subjects (↓apoA-2, ↓apoA-4, 
↓apoC-1, ↓apoC-3, ↓↑apoD, ↑ apoH, ↓apoL-1) two of which have been replicated 
(apoA2 and apoH) (Levin et al., 2010, Jaros et al., 2012, Domenici et al., 2010, Chan et al., 
2015, Sabherwal et al., 2016, Ramsey et al., 2013, Li et al., 2012). In keeping with these 
findings, a recent proteomic study of age 11 plasma from subjects who developed an 
extended broad psychosis phenotype at age 18 showed dysregulation of four 
apolipoproteins (↓apoA2, ↑apoH, ↑Đlu and ↑apoA4) (English et al., 2018a). Finally, apoD 
was found to be elevated in CHR subjects who transitioned to psychosis versus those who 
did not (Perkins et al., 2015). These changes suggest plasma apolipoprotein dysregulation is 
associated with not only current psychosis but also with a greater risk of future psychosis. 
Apolipoproteins are the main protein component of lipoproteins (chylomicrons, high-
density lipoprotein; HDL, intermediate density lipoprotein; IDL, low density lipoprotein; LDL, 
very low-density lipoprotein; VLDL and lipoprotein (a); Lp(a)). Different apolipoproteins are 
often associated with specific lipoproteins and can thus be involved in the transport of lipids 
for degradation (for example, apoA1 bound to HDL) or for deposition (for example, apoB 
bound to LDL). Many apolipoproteins are implicated in the pathology of cardiovascular 
disease, metabolic syndrome (Adiels et al. 2008), diabetes mellitus type II (Adiels et al. 2008) 
via dyslipidemia and stroke (for review on the assembly, structure, function of lipoproteins 
please see Hoofnagle and colleagues, 2009 (Hoofnagle & Heinecke 2009)).  
In the brain apolipoproteins function as lipid transporters, like in the periphery, but have 
additional roles in response to injury, myelin homeostasis, protection against oxidative 
stress and synaptic sprouting. ApoE is considered the major brain apolipoprotein and is the 
primary transporter of cholesterol in the CNS. ApoA1 and apoJ levels are the next most 
abundant in the CNS. It is generally thought that the brain does not produce apoA-I and that 
protein levels in the brain come from circulation (plasma apoA1/HDL levels reflect brain 
levels (Elliott et al., 2010)). Conversely, passage of apoE through the blood-brain barrier 
appears to be negligible (Shayo et al., 1997).  
In light of the evidence for dysregulated apolipoprotein expression within the blood in 
psychosis we have undertaken the first study in childhood bloods of those who have 
persisting psychotic experiences from early (age 11) to late childhood (age 18). Using a 
cutting edge proteomic approach and unique prospective cohort, we compared expression 
levels of 11 apolipoproteins between age 11 subjects who reported psychotic experiences at 
both age 11 and age 18 (n=38) compared to age-matched controls who experienced PEs at 
age 11 only (n=38), in the ALSPAC cohort. 
2. Materials and Methods
2.1 Participants 
Samples were obtained from the prospective general population cohort ALSPAC which 
contains demographic, environmental and clinical data on individuals involved.  Written 
informed consent was given prior to plasma sampling. Case and control samples were 
retrieved from the ALSPAC archive at the same time, stored under the same conditions, and 
tested iŶ a ͞ďliŶded͟ fashioŶ where saŵples froŵ the test groups were adŵixed. EthiĐal 
approval for the study was obtained from the ALSPAC Ethics and Law Committee and the 
Royal College of Surgeons in Ireland Research Ethics Committee (REC1240). Please see 
searchable data dictionary on the ALSPAC website for full details on all data obtained 
(www.bristol.ac.uk/alspac/researchers/access). 
2.2 Measures of PE and PD 
Psychotic Experiences (PEs) were measured by the semi-structured Psychosis-Like 
Symptoms (PLIKS) interview at ages 11 and 18. Interviews were conducted in assessment 
clinics by trained psychology graduates and PEs rated according to the definitions and rating 
rules from the Schedules for Clinical Assessment in Neuropsychiatry, Version 2.0 
(Organisation 1994) as not present, suspected or definite. We defined persistent psychotic 
experiences (PPE) as subjects who had PEs at age 11 and at age 18. 
2.3 Study Design 
Here, we conducted a nested case-control study comparing the plasma proteomic profiles 
at age 11 of those with PEs at age 11 and age 18 (n=38) in comparison to
age 11 but not age 18 (n=38). See Table 1 for details on grouping. With regards to 
psychotropic drug use two subjects were recorded as taking psychotropic drugs. No subjects 
reported psychotropic drug use at age 11. The present study consisted of analyses of two 
distinct datasets harbouring mass-spectrometry based proteomic profiles.  
2.4 Blood collection  
For all ALSPAC participants, blood samples from non-fasting individuals were collected at 
approximately 12 years of age. Blood was collected in 7.5ml Plasma Lithium-Heparin S-
Monovette tubes (Sarstedt). Once collected, samples were stored on ice for a maximum of 
90 min until processed. After centrifugation, the plasma was stored in aliquots at -80°C. All 
samples underwent a single freeze thaw cycle in order to aliquot prior to the study. The 
standard quality of the plasma samples was ensured by assessing the overall MS protein 
profile in order to facilitate the identification of outlier protein expression profiles (see 
Supplementary Figure 1). 
2.5 High-Abundance Protein Depletion of Plasma Samples 
To improve the dynamic range for proteomic analysis, 40µl of plasma from each case in all 
samples was immunodepleted of the 14 most abundant proteins (Alpha-1-antitrypsin, A1-
acid glycoprotein, Serum Albumin, Alpha2-macroglobulin, Apolipoprotein A-I, 
Apolipoptrotein A-II, Complement C3, Fibrinogen alpha/beta/gamma, Haptoglobin, IgG A, 
IgG G, IgG M, Transthyretin, and Serotransferrin), using the Agilent Hu14 Affinity Removal 
System (MARS) coupled to a High Performance Liquid Chromatography (HPLC) system (Levin 
et al., 2010) (see Supplementary Methods).  
2.6 Sample Preparation for Mass Spectrometry  
Protein digestion and peptide purification was performed as previously described (English et 
al., 2015), and is further detailed in Supplementary Methods.  
2.7 Proteomic analysis  
We used the semi-targeted approach of Data Independent Acquisition (DIA) to target all 23 
human apolipoproteins with UniProt identifiers. 12 of these showed poor chromatography 
and were thus excluded (see bioinformatic analysis), leaving 11. DIA overcomes many of the 
limitations of untargeted proteomics, for example missing values (Sajic et al., 2015, Liu et 
al., 2015, Aebersold et al., 2016, Teo et al., 2015). ϱμl of eaĐh saŵple (5μg protein) was 
injected on the Thermo Scientific Q-Exactive, connected to a Dionex Ultimate 3000 
(RSLCnano) chromatography system, and data was acquired in DIA mode. The DIA isolation 
scheme and multiplexing strategy (MSx) was based on that from Egertson et al., in which 
five separate 4-m/z isolation windows are analysed per spectrum.  
In order to create a spectral library for targeted chromatogram extraction, we used an 
internal standard for quality control (QC), where an equal aliquot from each protein digest 
in the experiment was pooled into one sample for use as an internal QC. QC samples were 
injected in data-dependent acquisition (DDA) mode and was injected three times at the 
beginning of the MS study to condition the column, and subsequently after every ten 
injections throughout the experiment to monitor the MS performance. To facilitate accurate 
prediction of peptide retention calculation in Skyline
TM
 for DIA data, protein digests were 
spiked with the Pierce
TM
 Peptide ‘eteŶtioŶ Tiŵe CaliďratioŶ Mixture ;ϰ fŵol/μlͿ, aĐĐordiŶg 
to the ŵaŶufaĐturers͛ iŶstruĐtioŶs.  
2.8 ApoE quantitation by ELISA 
For quantitative detection of human apoE in the non-depleted plasma samples of patients 
with PPE, and controls, we used Apolipoprotein E Human ELISA Kit (ready-to-use sandwich 
ELISA) with a sensitivity of 1.5 ng/ml and a detection range of 1.64 ng/ml - 400 ng/ml  
(ThermoFisher Scientific) iŶ aĐĐordaŶĐe with the ŵaŶufaĐturer͛s iŶstruĐtioŶs. For 
quantitative detection of human ApoE in the non-depleted plasma samples of patients with 
PPE, and controls, samples were analysed using a Human Apo E (AD2) ELISA Kit (ready to use 
sandwich ELISA) from ThermoFisher “ĐieŶtifiĐ iŶ aĐĐordaŶĐe with the ŵaŶufaĐturer͛s 
instructions. Plasma samples were diluted 1 in 1000 before analysis. Standard curve 
detection ranged from 1.64ng/mL to 400ng/mL.  
2.9 Bioinformatic and statistical analysis 
Using the open-source software Skyline we performed targeted spectral library-based 
extraction of peptides from the data acquired by DIA. In addition, all peptide and fragment 
ions were visually checked and peak integration performed according to the method used 
by English and colleagues (see supplementary document from (English et al., 2018a)). All 
apolipoproteins with Uniprot accession numbers were extracted. Filtration of fragment ions 
and generation of protein-level data was undertaken in mapDIA (Teo et al., 2015).  For a full 
list of the fragments targeted and quantified, please refer to Supplementary Table 1. See 
supplementary methods for more detail on data handling. Statistical analysis was performed 
in SPSS by univariate analysis using one-way ANCOVA, with BMI and Gender included as 
covariates. There was a significant difference in gender distribution between groups, unlike 
BMI. We adjusted for BMI as the prevalence of obesity in people with mental illness has 
been reported to be higher than the general population and recent evidence suggests low 
childhood BMI between the ages 7 and 13 years is associated with risk of schizophrenia 
(Sorensen et al., 2016, Chouinard et al., 2016). Furthermore, apoE has been shown to 
correlate with BMI (Sofat et al., 2016). FDR correction, at 5% cut-off, was performed using 
the Benjamini-Hochberg procedure (Benjamini and Hochberg, 1995). 
For the validation experiment statistics were performed using GraphPad Prism. Specifically, 
a Mann Whitney t-test (non-parametric and two-tailed) was performed.  
3. Results
3.1 Proteomic analysis of PPEs 
Using a semi-targeted proteomic approach, expression levels of 11 apolipoproteins (APOA1, 
(APOA2, APOA4, APOB, APOC1, APOC2, APOC3, APOC4, APOE, APOH, CLU) were compared 
between participants with PEs at ages 12 and 18 (n=38) and control subjects who had PEs 
only at age 11 (n=38; Table 1). No PPE cases or controls were excluded from the 
bioinformatic analysis. Originally, we sought to compare expression levels of all known 
apolipoproteins (23), however due to sub-threshold detection levels (APOL2-6, APOD, 
APOA5, APOO), poor chromatography (APOM, LPA, APOF) or filtration due to variability 
(APOM, LPA) 12 of these were excluded from our analysis. We identified apoE to be 
significantly differentially expressed between cases and controls (p-value = 0.003 
[Benjamini-Hochberg adjusted p-value p< 0.03]; Table 2 and Figure 1). The protein was 
found to be upregulated in those with persistent psychotic experiences. 
Using ELISA we confirmed the MS result of apoE upregulation in PPE group (n=38) compared 
to control (n=37) (p-value 0.034; Figure 2). 
4. Discussion
Apolipoproteins have been shown to be dysregulated in blood, brain and CSF in 
schizophrenia (Sabherwal et al., 2016, Martins-De-Souza et al., 2010, Dean et al., 2003, 
Thomas et al., 2001, Huang et al., 2008). Our study is the first to assess and to show changes 
in apolipoprotein expression levels in the plasma of children at age 11 with psychotic 
experiences that persisted to age 18. We found that altered expression of plasma apoE at 
age 11 is associated with the persistence of psychotic experiences at age 18. Because 
subjects who report psychotic experiences (PEs) are at increased risk not solely for 
schizophrenia but for other major psychiatric disorders such as depression and anxiety 
disorders (Rutigliano et al., 2016, Kelleher et al., 2012), our findings are of broad relevance 
to adult psychiatric syndromes.  
Previous studies of neuroleptic naïve and chronic schizophrenia have implicated apoE in the 
disorder. Increased phosphorylation of an apoE peptide was found in the serum of FEP 
(antipsychotic naïve) patients compared to healthy controls (Jaros et al., 2012). Further, 
elevated apoE expression, consistent with our own findings, has been reported in studies 
involving brain and cerebrospinal fluid of non-medicated schizophrenia patients (Dean et al., 
2003, Martins-De-Souza et al., 2010). While there is debate whether the level of apoE in 
blood reflects the cerebral level, CSF apoE has been estimated at 10-20% of the level in 
plasma despite their regulation by two parallel but metabolically different compartments 
(Cruchaga et al., 2012, Ulrich et al., 2013, Mahley, 2016). As such, our finding may reflect 
enhanced CSF apoE in children who will experience persisting psychotic experiences at ages 
12 and 18.  
Previous findings are not entirely consistent as plasma apoE was found to be reduced in 
those with schizophrenia (Dean et al., 2008). Possible explanations for these contrasting 
results include study population differences relating to past and current antipsychotic drug 
treatment and age, since these have been shown to affect apoE levels (Vik-Mo et al., 2009, 
Rasmussen, 2016). Furthermore, apoE was not shown to be altered in the blood of 
schizophrenia patients in a discovery mass-spectrometry study carried out in blood of 
subjects with schizophrenia (Yang et al., 2006). However, methodological differences may 
account for this, such as sensitivity of instrumentation and sampling and depletions 
methods, and contrasting medication status of subjects with psychotic illness (critically our 
study included only plasma samples from subjects at age 11 and no psychotropic medication 
had been prescribed for them).  
ApoE is functionally diverse and several mechanisms may underlie the elevation in plasma 
levels observed in the current study. Its primary function is in the transport and metabolism 
of dietary lipids, mainly triglycerides in plasma, from the intestines to other locations in the 
body. Indeed a strong association has been shown between apoE and lipid levels within the 
brain with speculation that apoE possibly in conjunction with reelin maintains and regulates 
synaptic plasticity (Beasley et al., 2017). Plasma apoE is synthesized in the liver 
predominantly and to a lesser degree in circulating macrophages (Mooijaart et al., 2006). 
Hypertriglyceridemic patients have been found to have higher plasma levels of apoE 
compared with healthy control subjects (Huang et al., 1998b, Sofat et al., 2016, Vincent-Viry 
et al., 1998). This may be because increased levels of apoE stimulate VLDL triglyceride 
production in the liver and impair lipoprotein lipase-mediated lipolysis (Huang et al., 1998b, 
Huang et al., 1998a). Therefore, our finding that plasma apoE is upregulated in those with 
PPEs is consistent with the finding of a recent meta-analysis which showed elevated 
triglycerides in FEP (Pillinger et al., 2017), and with another study showing TGs are elevated 
at age 11 among apparently well children who report PEs at age 18 (Pillinger et al., 2017, 
O'Gorman et al., 2017). Plasma apoE is also involved in cholesterol rich HDL endocytosis in 
the liver. Total cholesterol levels have been shown to be reduced in FEP which is consistent 
with our finding in that enhanced apoE may result in increased cholesterol rich HDL 
breakdown (Pillinger et al., 2017).  
ApoE is also thought to play a role in the immune response, specifically in inflammation. 
Plasma levels of apoE are increased up to 4-fold in response to lipopolysaccharide (LPS) 
induced inflammation in mice despite sharply decreased apoE gene expression in the liver, 
macrophages, and extrahepatic tissues (suggesting high plasma apoE levels were not due to 
increased synthesis in liver tissue (Li et al., 2008)). It has therefore been hypothesized that 
LPS induced inflammation may result in reduced apoE clearance and accumulation in the 
blood (Fu et al., 2014). In addition, there is now evidence for complement pathway 
regulation by apoE through interactions between apoE and complement factor H (CFH) of 
the alternative complement pathway (Haapasalo et al., 2015). The complement pathway 
has a prominent role in inflammation (Markiewski and Lambris, 2007, Orsini et al., 2014, 
Kolev et al., 2014) and has been shown to be dysregulated in plasma prior to the onset of 
psychosis (English et al., 2018b) and in schizophrenia and FEP bloods (Li et al., 2012, 
Kopczynska et al., 2017) 
Other mechanisms by which apoE could be involved in psychotic experiences are via HPA-
axis regulation, blood-brain barrier regulation and its effects on cognition. There is evidence 
for apoE levels reflecting HPA-axis stimulation including the finding that dexamethasone, a 
synthetic glucocorticoid, increased the secretion of apoE from macrophages in plasma 
(Zuckerman et al., 1993). In addition, cortisol and apoE4 have also been found to interact in 
cognitive decline during aging in that in the presence of the apoE4 allele cortisol levels are 
associated more strongly with cognitive scores (Lee et al., 2008). ApoE has been associated 
with transition to dementia from mild cognitive impairment (Hye et al., 2014). This is 
relevant to the current study considering the role of stress and HPA-axis dysregulation in 
psychosis risk (Cotter and Pariante, 2002). ApoE is also relevant to psychosis risk through its 
impact on the integrity of the blood brain barrier (implicated in schizophrenia) (Pollak et al., 
2018). ApoE knockout mice exhibit impaired blood-brain barrier integrity (Fullerton et al., 
2001) and knockout mice are also vulnerable to psychosis-related behavioural responses 
following administration of human NMDAR-AB (Hammer et al., 2014). Finally, plasma apoE 
levels impact on cognition and synaptic function (Lane-Donovan et al., 2016), findings which 
may be relevant to the cognitive changes found among CHR subjects who transition to 
psychotic disorder (disorganized communication, poor social functioning and verbal 
memory deficits in particular) (Addington et al., 2017) and among subjects who report 
psychotic experiences at age 11 (processing speed and attention in particular) (Niarchou et 
al., 2013).  
ApoE is involved in other psychiatric disorders. The APOE4 allele has a strong association 
with Alzheiŵer͛s Disease (Kim et al., 2009). Protein expression levels have also been 
researĐhed iŶ Alzheiŵer͛s Disease, dementia and in relation to cognition. While the results 
of these studies in blood are somewhat inconsistent, most evidence now points to low 
plasma apoE predicting dementia and low plasŵa apoE as a ďioŵarker for Alzheiŵer͛s 
disease (Rasmussen, 2016). Increased plasma apoE has also been shown correlate with 
severity of suicidal behaviour (Asellus et al., 2016). The authors hypothesized this may be 
related to the regulation of apoE by stress and the role of stress in suicide severity. The 
findings in Alzheiŵer͛s disease aŶd suicidal patients also raise the question of whether apoE 
elevation in plasma is a biomarker of psychiatric illness more broadly. Given that the current 
study focusses on subjects who report PEs (not psychotic disorder) and in the knowledge 
that PEs in childhood are related to a range of non -psychiatric outcomes, including suicide 
(Heinze et al., 2018, Kelleher et al., 2014a, Kelleher et al., 2014b), our current findings 
support the view that elevated plasma apoE is associated with vulnerability to psychiatric 
disorders generally. 
Our study has several weaknesses. Firstly, plasma apoE elevation has not previously been 
reported in medication-free schizophrenia by mass-spectrometry. This however is because 
most recent studies have not reported apoE quantitation (Levin et al., 2010, Li et al., 2012, 
Zhou et al., 2014, Ding et al., 2015). Secondly, apoE in humans has several isoforms and 
therefore protein identification based on molecular weight (as in proteomic methods) can 
be confounded by the different forms of apoE (Hussain et al., 1989). However, we used 
ELISA to confirm our findings and therefore we are confident in the results. Thirdly, we 
undertook depletion of the 14 most abundant plasma proteins before mass spectrometry 
analysis, including apoA1 and apoA2 and therefore expression levels of these two proteins 
should be viewed with caution. Fourthly, our study utilised the uniquely characterised 
ALSPAC cohorts and we could not access a similar age-matched sample in which we could 
perform a direct replication. Finally, apoE has also been the target of schizophrenia genetic 
studies and recent meta-analysis showed no significant contribution of APOE4 allele to 
schizophrenia risk (Gonzalez-Castro et al., 2015). However, the APOE polymorphism 
accounts for just 15-25% of the variability of plasma levels (Rasmussen, 2016). There is also 
evidence that the APOE4 polymorphism specifically modifies the expression of positive 
symptoms in schizophrenia (Malhotra et al., 1998). 
Here we have found plasma apoE to be upregulated in children at age 11 who report 
persisting psychotic experiences at age 18, compared to children whose PEs do not persist. 
This is a novel finding which may provide insight into the pathophysiology of PEs and their 
outcome. It is consistent with recent evidence that lipid metabolism is important in the early 
stages of psychosis, such as FEP and UHR (McGorry et al., 2014, Amminger et al., 2010, 
Smesny et al., 2014). Indeed, plasma apoE elevation may reflect disruption in lipid 
homeostasis but also disturbed inflammation, cognition, blood-brain barrier homeostasis 
and/or HPA axis regulation. Future investigations are required to confirm and further 
elucidate on the relationship of apoE to these processes among those with PEs.  
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Figure Legends 
Figure 1: Protein expression changes determined by mass-spectrometry for apoE. Increased 
expression in persistent psychotic experiences group (38) versus the non-persistent group 
(38) (p-value 0.003[Benjamini-Hochberg adjusted p-value p< 0.03])
Figure 2: Plasma samples were analysed using a human ApoE ELISA. The graph is 
representative of plasma from 38 Control Subjects and 37 Persistent Psychotic Experience 
(PPE) Subjects. Statistical analysis was performed using a non-parametric Mann Whitney T-
test. Statistical significance was considered when *p<0.05 (p-value 0.0364). 
Tables legends 
Table 1: Descriptive information for ALSPAC subjects.  
For Gender F = Female, M = Male. Body Mass Index (BMI) at age 11 is reported, where missing BMI 
variables were replaced with the mean according to gender. PLIKS at age 11 and age 18 are 
reported. For Depression a binary outcome was resported: individuals with CIS-R scores >= 7 as 
depression (D) and <7 as no depression (ND).   
Table 2. Differential Protein Expression in PPE. Semi-targeted proteomic analysis of 12 biomarker 
candidates in the PPE cohort of cases (n=38) and controls (n=38). Protein level data was assessed for 
significance and Apolipoportien E and Clusterin were identified as significantly differentially 
expressed between cases and controls following adjustment for gender, BMI and multiple 
comparisons. The protein ID (accession), protein name, gene name, unadjusted and adjusted p-
values, fold change (FC) in disorder, and benjamini-hochberg adjusted p-values with FDR cut-off of 
0.05 values are listed for all 12 proteins profiled. Proteins are sorted by p-value. 
Figure 1: Protein expression changes determined by mass-spectrometry for apoE. Increased 
expression in persistent psychotic experiences group (38) versus the non-persistent group (38) 
(p-value 0.003[Benjamini-Hochberg adjusted p-value p< 0.03]). 
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Figure 2: Plasma samples were analysed using a human ApoE ELISA. The graph is 
representative of plasma from 38 Control Subjects and 37 Persistent Psychotic Experience 
(PPE) Subjects. Statistical analysis was performed using a non-parametric Mann Whitney T-
test. Statistical significance was considered when *p<0.05 (p-value 0.0364). 
Figure 2
Table 1: Descriptive information for ALSPAC subjects.  
For Gender F = Female, M = Male. Body Mass Index (BMI) at age 11 is reported, where missing BMI 
variables were replaced with the mean according to gender. PLIKS at age 11 and age 18 are reported. 
For Depression a binary outcome was resported: individuals with CIS-R scores >= 7 as depression (D) and 
<7 as no depression (ND).   
Persisting Psychotic Experiences ( ) Study 
Cases 
(PE12=Def/Sus, 
PE18=Def) 
Controls 
(PE12=Def/Sus, 
PE18=0) 
Proteomics Study 38 38 
Gender 26F, 11M 23F, 15M 
BMI at age 11 
Mean (StdDev) 
18.67 (3.55) 18.46 (2.77) 
Ethnicity 32W, 1NW, 4 NA 36W, 2NW 
Pliks at age 11 20 Sus, 17 Def 27 Sus, 11 Def 
Pliks at age 18 37 Definite 38 None 
Social Economic Status 18NM, 12M, 7 NA 26NM, 12M 
Depression at age 18 5ND, 30D, 2NA 20ND, 16D, 2NA 
Received medication for hallucinations/delusions at 
age 18 
2 Yes, 35 NA NA 
Delusions only happened when within 2 hours of 
drinking alcohol/taking drugs 
 (Definitely Present/Not Present/NA) 
1/18/18 NA 
Table 1
Table 2. Differential Protein Expression in PPE. Semi-targeted proteomic analysis of 12 biomarker 
candidates in the PPE cohort of cases (n=38) and controls (n=38). Protein level data was assessed for 
significance and Apolipoportien E and Clusterin were identified as significantly differentially 
expressed between cases and controls following adjustment for gender, BMI and multiple 
comparisons. The protein ID (accession), protein name, gene name, unadjusted and adjusted p-
values, fold change (FC) in disorder, and benjamini-hochberg adjusted p-values with FDR cut-off of 
0.05 values are listed for all 12 proteins profiled. Proteins are sorted by p-value. 
Protein 
ID 
Protein name Gene 
name 
P-value
a 
FC (case/control) FDR 
P02649 Apolipoprotein E Apo-E 0.0027 1.3361 0.0297 
P10909 Clusterin/Apolipoprotein 
J 
Clus 0.0343 1.1446 0.1886 
P02749 Apolipoprotein H Apo-H 0.0533 0.7826 0.1953 
P02656 Apolipoprotein C3 Apo-
C3 
0.1882 0.8850 0.5176 
P04114 Apolipoprotein B Apo-B 0.2026 1.0503 0.4458 
P06727 Apolipoprotein A4 Apo-
A4 
0.4254 1.0726 0.7800 
P02655 Apolipoprotein C2 Apo-
C2 
0.3374 1.1395 0.5302 
P02652 Apolipoprotein A2 Apo-
A2 
0.6209 0.8104 0.8538 
P55056 Apolipoprotein C4 Apo-
C4 
0.7065 0.9130 0.8634 
P02647 Apolipoprotein A1 Apo-
A1 
0.9781 0.9910 1.0759 
P02654 Apolipoprotein C1 Apo-
C1 
0.8787 0.9998 0.8787 
a 
BMI and gender adjusted p-value 
Table 2
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